VM4 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Fanapt Commercial MomentumFanapt is showing durable commercial traction, supported by higher sales, prescription growth, and stronger new-to-brand demand. Expansion into bipolar I disorder and broader sales-force coverage can extend the product’s addressable market and help sustain branded revenue over the next several quarters.
Pipeline And Portfolio ExpansionMultiple approved, launch-ready, and late-stage assets give Vanda several avenues to diversify beyond its existing products. BYSANTI’s exclusivity and planned launch, together with NEREUS and Quimilza opportunities, could broaden revenue sources and improve portfolio durability.
Low Balance-Sheet LeverageVery low leverage provides financial flexibility compared with a debt-heavy pharmaceutical model and reduces the immediate burden of interest and refinancing obligations. This cushion can support commercialization and development spending, although its benefit depends on slowing the company’s ongoing losses and cash consumption.
Bears Say
Elevated Cash BurnRapid cash depletion combined with an expectation of higher annual burn creates a meaningful funding and runway risk. Continued investment in launches and clinical programs may require difficult capital-allocation decisions, especially if new products do not scale quickly enough to offset spending.
Severe Profitability DeteriorationThe sharp move from near-breakeven results to heavy losses indicates weak current operating leverage and makes revenue growth less valuable until expenses normalize. Persistent losses can erode equity, consume liquidity, and limit Vanda’s ability to fund its broad product and development agenda internally.
HETLIOZ Generic CompetitionGeneric competition is reducing revenue from a marketed product that remains an important part of the portfolio. Continued volume erosion, with management warning that declines could become significant, may weaken the recurring revenue base and increase reliance on newer products and launches.
Vanda News
VM4 FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Currently, no data Available
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is CHF188.81M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Feb 10, 2027 which is in 101 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Oct 28, 2026. The company reported -CHF0.305 earnings per share for the quarter, beating the consensus estimate of -CHF0.562 by CHF0.257.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.3.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 60,462,690 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -CHF0.305 in its last earnings report, beating expectations of -CHF0.562. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in CH:VM4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vanda Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF10.96 (― Upside)
CHF10.96 (― Upside)
Blogger Sentiment
Bullish
CH:VM4 Sentiment 89%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.26%
12-Months-Change
Fundamentals
Return on Equity
-106.94%
Trailing 12-Months
Asset Growth
-36.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
VM4 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive, supported by 24% third-quarter revenue growth, strong Fanapt prescription trends, positive NEREUS and HETLIOZ clinical results, the expected BYSANTI launch, the Quimilza regulatory milestone, and declining quarterly operating expenses. These positives were partly offset by a larger year-to-date net loss, a substantial cash balance decline, expected higher 2026 cash burn, continued generic pressure on HETLIOZ, constrained early NEREUS revenue, and ongoing regulatory proceedings.View all CH:VM4 earnings summariesVM4 Stock 12 Month Forecast
Average Price Target
―Omeros
―
Aldeyra Therapeutics
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Alector
―